234 related articles for article (PubMed ID: 9824101)
1. Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma.
Lynch BJ; Komaromy-Hiller G; Bronstein IB; Holden JA
Hum Pathol; 1998 Nov; 29(11):1240-5. PubMed ID: 9824101
[TBL] [Abstract][Full Text] [Related]
2. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression.
Monnin KA; Bronstein IB; Gaffney DK; Holden JA
Hum Pathol; 1999 Apr; 30(4):384-91. PubMed ID: 10208458
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas.
Hafian H; Venteo L; Sukhanova A; Nabiev I; Lefevre B; Pluot M
Hum Pathol; 2004 Jun; 35(6):745-51. PubMed ID: 15188142
[TBL] [Abstract][Full Text] [Related]
4. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Staley BE; Samowitz WS; Bronstein IB; Holden JA
Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas.
Coleman LW; Bronstein IB; Holden JA
Anticancer Res; 2001; 21(2A):1167-72. PubMed ID: 11396158
[TBL] [Abstract][Full Text] [Related]
6. Human DNA topoisomerase I: An anticancer drug target present in human sarcomas.
Coleman LW; Rohr LR; Bronstein IB; Holden JA
Hum Pathol; 2002 Jun; 33(6):599-607. PubMed ID: 12152158
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival.
Holden JA; Townsend JJ
Mod Pathol; 1999 Dec; 12(12):1094-100. PubMed ID: 10619260
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
Gupta D; Shidham V; Holden J; Layfield L
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):267-74. PubMed ID: 11127918
[TBL] [Abstract][Full Text] [Related]
9. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.
Mu XC; Tran TA; Ross JS; Carlson JA
J Cutan Pathol; 2000 May; 27(5):242-8. PubMed ID: 10847549
[TBL] [Abstract][Full Text] [Related]
11. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer.
Lynch BJ; Guinee DG; Holden JA
Hum Pathol; 1997 Oct; 28(10):1180-8. PubMed ID: 9343325
[TBL] [Abstract][Full Text] [Related]
12. p53 dependence of topoisomerase I recruitment in vivo.
Mao Y; Okada S; Chang LS; Muller MT
Cancer Res; 2000 Aug; 60(16):4538-43. PubMed ID: 10969804
[TBL] [Abstract][Full Text] [Related]
13. Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas.
Coleman LW; Perkins SL; Bronstein IB; Holden JA
Hum Pathol; 2000 Jun; 31(6):728-33. PubMed ID: 10872667
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate.
Willman JH; Holden JA
Prostate; 2000 Mar; 42(4):280-6. PubMed ID: 10679757
[TBL] [Abstract][Full Text] [Related]
15. Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms.
Gupta D; Shidham V; Holden J; Layfield L
Appl Immunohistochem Mol Morphol; 2001 Sep; 9(3):215-21. PubMed ID: 11556748
[TBL] [Abstract][Full Text] [Related]
16. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
[TBL] [Abstract][Full Text] [Related]
17. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
[TBL] [Abstract][Full Text] [Related]
18. Expression of DNA topoisomerase IIalpha in thyroid neoplasia.
Lee A; LiVolsi VA; Baloch ZW
Mod Pathol; 2000 Apr; 13(4):396-400. PubMed ID: 10786805
[TBL] [Abstract][Full Text] [Related]
19. Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Hirata S; Katoh O; Oguri T; Watanabe H; Yajin K
Jpn J Cancer Res; 2000 Jan; 91(1):84-90. PubMed ID: 10744048
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of DNA topoisomerase II alpha and II beta genes between small cell and non-small cell lung cancer.
Syahruddin E; Oguri T; Takahashi T; Isobe T; Fujiwara Y; Yamakido M
Jpn J Cancer Res; 1998 Aug; 89(8):855-61. PubMed ID: 9765623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
